These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36982690)

  • 61. Digging into the lesser-known aspects of CRISPR biology.
    Guzmán NM; Esquerra-Ruvira B; Mojica FJM
    Int Microbiol; 2021 Nov; 24(4):473-498. PubMed ID: 34487299
    [TBL] [Abstract][Full Text] [Related]  

  • 62. On the Origin of Reverse Transcriptase-Using CRISPR-Cas Systems and Their Hyperdiverse, Enigmatic Spacer Repertoires.
    Silas S; Makarova KS; Shmakov S; Páez-Espino D; Mohr G; Liu Y; Davison M; Roux S; Krishnamurthy SR; Fu BXH; Hansen LL; Wang D; Sullivan MB; Millard A; Clokie MR; Bhaya D; Lambowitz AM; Kyrpides NC; Koonin EV; Fire AZ
    mBio; 2017 Jul; 8(4):. PubMed ID: 28698278
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lentiviral vectors and antiretroviral intrinsic immunity.
    Mangeat B; Trono D
    Hum Gene Ther; 2005 Aug; 16(8):913-20. PubMed ID: 16076249
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quorum Sensing Controls Adaptive Immunity through the Regulation of Multiple CRISPR-Cas Systems.
    Patterson AG; Jackson SA; Taylor C; Evans GB; Salmond GPC; Przybilski R; Staals RHJ; Fineran PC
    Mol Cell; 2016 Dec; 64(6):1102-1108. PubMed ID: 27867010
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative genomics reveals the diversity of CRISPR-Cas locus in Azotobacter organisms.
    Karmakar K; Kumar S; Roy D; Singh M; Kolte V; Choudhury A; Sharma G
    Lett Appl Microbiol; 2023 Jan; 76(1):. PubMed ID: 36688751
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Why put up with immunity when there is resistance: an excursion into the population and evolutionary dynamics of restriction-modification and CRISPR-Cas.
    Gurney J; Pleška M; Levin BR
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180096. PubMed ID: 30905282
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Innate and adaptive immunity in bacteria: mechanisms of programmed genetic variation to fight bacteriophages.
    Bikard D; Marraffini LA
    Curr Opin Immunol; 2012 Feb; 24(1):15-20. PubMed ID: 22079134
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The CRISPR conundrum: evolve and maybe die, or survive and risk stagnation.
    García-Martínez J; Maldonado RD; Guzmán NM; Mojica FJM
    Microb Cell; 2018 May; 5(6):262-268. PubMed ID: 29850463
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The CRISPRs, they are a-changin': how prokaryotes generate adaptive immunity.
    Westra ER; Swarts DC; Staals RH; Jore MM; Brouns SJ; van der Oost J
    Annu Rev Genet; 2012; 46():311-39. PubMed ID: 23145983
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Annotation and Classification of CRISPR-Cas Systems.
    Makarova KS; Koonin EV
    Methods Mol Biol; 2015; 1311():47-75. PubMed ID: 25981466
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Methods for the Analysis and Characterization of Defense Mechanisms Against Horizontal Gene Transfer: CRISPR Systems.
    Calvo-Villamañán A; Bernheim A; Bikard D
    Methods Mol Biol; 2020; 2075():235-249. PubMed ID: 31584167
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Substrate generation for endonucleases of CRISPR/cas systems.
    Zoephel J; Dwarakanath S; Richter H; Plagens A; Randau L
    J Vis Exp; 2012 Sep; (67):. PubMed ID: 22986408
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Evolutionary dynamics of the prokaryotic adaptive immunity system CRISPR-Cas in an explicit ecological context.
    Iranzo J; Lobkovsky AE; Wolf YI; Koonin EV
    J Bacteriol; 2013 Sep; 195(17):3834-44. PubMed ID: 23794616
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Microbial Arsenal of Antiviral Defenses. Part II.
    Isaev AB; Musharova OS; Severinov KV
    Biochemistry (Mosc); 2021 Apr; 86(4):449-470. PubMed ID: 33941066
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases.
    Garcia-Robledo JE; Barrera MC; Tobón GJ
    Int Rev Immunol; 2020; 39(1):11-20. PubMed ID: 31625429
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Expanding the catalog of cas genes with metagenomes.
    Zhang Q; Doak TG; Ye Y
    Nucleic Acids Res; 2014 Feb; 42(4):2448-59. PubMed ID: 24319142
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Broad Targeting Specificity during Bacterial Type III CRISPR-Cas Immunity Constrains Viral Escape.
    Pyenson NC; Gayvert K; Varble A; Elemento O; Marraffini LA
    Cell Host Microbe; 2017 Sep; 22(3):343-353.e3. PubMed ID: 28826839
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The CRISPR Growth Spurt: from Bench to Clinic on Versatile Small RNAs.
    Bayat H; Omidi M; Rajabibazl M; Sabri S; Rahimpour A
    J Microbiol Biotechnol; 2017 Feb; 27(2):207-218. PubMed ID: 27840399
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunity, suicide or both? Ecological determinants for the combined evolution of anti-pathogen defense systems.
    Iranzo J; Lobkovsky AE; Wolf YI; Koonin EV
    BMC Evol Biol; 2015 Mar; 15():43. PubMed ID: 25881094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.